Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to -$96.6 million.

  • Nuvation Bio's Cash from Investing Activities fell 43184.85% to -$96.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.2 million, marking a year-over-year decrease of 3831.63%. This contributed to the annual value of $122.7 million for FY2024, which is 127544.0% up from last year.
  • As of Q3 2025, Nuvation Bio's Cash from Investing Activities stood at -$96.6 million, which was down 43184.85% from $54.9 million recorded in Q2 2025.
  • Over the past 5 years, Nuvation Bio's Cash from Investing Activities peaked at $54.9 million during Q2 2025, and registered a low of -$96.6 million during Q3 2025.
  • In the last 3 years, Nuvation Bio's Cash from Investing Activities had a median value of $33.2 million in 2023 and averaged $13.1 million.
  • Examining YoY changes over the last 5 years, Nuvation Bio's Cash from Investing Activities showed a top increase of 61840.36% in 2025 and a maximum decrease of 43184.85% in 2025.
  • Over the past 3 years, Nuvation Bio's Cash from Investing Activities (Quarter) stood at $33.2 million in 2023, then soared by 56.11% to $51.8 million in 2024, then crashed by 286.63% to -$96.6 million in 2025.
  • Its Cash from Investing Activities was -$96.6 million in Q3 2025, compared to $54.9 million in Q2 2025 and $54.2 million in Q1 2025.